Core Viewpoint - The arbitration case regarding the exclusive agency rights for AestheFill products has seen new developments, with REGEN Biotech, Inc. receiving a decision from the Shenzhen International Arbitration Court that revokes previous temporary measures against them, although the case is still under review [2][8]. Group 1: Arbitration Developments - On January 30, 2026, REGEN received a decision from the Shenzhen International Arbitration Court that revoked the temporary measures imposed on September 10, 2025, which restricted REGEN from selling AestheFill products in China and recognized DaTou Company as the exclusive distributor [2][8]. - The temporary measures had been in place since a request from DaTou Company, which claimed exclusive rights to AestheFill products in China [7][8]. - The arbitration case is ongoing, and the recent decision does not represent a final ruling on the matter [8]. Group 2: Company Actions and Responses - DaTou Company was granted exclusive distribution rights for AestheFill products in mainland China through an agreement signed in August 2022 [3]. - In July 2025, REGEN sent a termination notice to DaTou, claiming violations of the agreement and citing reputational damage due to actions by DaTou's parent company, Jiangsu Wuzhong [4][5]. - Jiangsu Wuzhong has publicly defended DaTou's rights, asserting that the exclusive agency agreement remains valid until August 28, 2032 [4]. Group 3: Financial Performance - Jiangsu Wuzhong's stock was delisted on December 31, 2025, due to significant financial irregularities, including inflated revenues and undisclosed related-party transactions [9]. - AestheFill sales accounted for 20.42% of Jiangsu Wuzhong's revenue in 2024, with a significant contribution to its gross profit [10]. - For the first three quarters of 2025, Jiangsu Wuzhong reported a 38.85% decline in revenue, leading to a net loss [10]. Group 4: Market Context - Aimeike, the parent company of REGEN, has experienced declining revenue and net profit, with a 21.49% drop in revenue for the first three quarters of 2025 [11]. - The overall medical aesthetics market in China is facing slower growth, attributed to increased competition and a challenging macroeconomic environment [11].